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Abstract
Background: Left ventricular mass (LVM) is an important risk factor for stroke and vascular
disease. The genetic basis of LVM is unclear although a high heritability has been suggested. We
sought to map quantitative trait loci (QTL) for LVM using large Dominican families.
Methods: Probands were selected from Dominican subjects of the population-based Northern
Manhattan Study (NOMAS). LVM was measured by transthoracic echocardiography. A set of 405
microsatellite markers was used to screen the whole genome among 1360 subjects from 100
Dominican families who had complete phenotype data and DNA available. A polygenic covariate
screening was run to identify the significant covariates. Variance components analysis was used to
estimate heritability and to detect evidence for linkage, after adjusting for significant risk factors.
Ordered-subset Analysis (OSA) was conducted to identify a more homogeneous subset for
stratification analysis.
Results: LVM had a heritability of 0.58 in the studied population (p < 0.0001). The most significant
evidence for linkage was found at chromosome 12p11 (MLOD = 3.11, empirical p = 0.0003) with
peak marker at D12S1042. This linkage was significantly increased in a subset of families with the
high average waist circumference (MLOD = 4.45, p = 0.0045 for increase in evidence for linkage).
Conclusion: We mapped a novel QTL near D12S1042 for LVM in Dominicans. Enhanced linkage
evidence in families with larger waist circumference suggests that gene(s) residing within the QTL
interact(s) with abdominal obesity to contribute to phenotypic variation of LVM. Suggestive
evidence for linkage (LOD = 1.99) has been reported at the same peak marker for left ventricular
geometry in a White population from the HyperGEN study, underscoring the importance of this
QTL for left ventricular phenotype. Further fine mapping and validation studies are warranted to
identify the underpinning genes.
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Stroke and cardiovascular diseases are of major public
health concern, particularly among the rapidly growing
Hispanic population [1]. Studies have shown that a posi-
tive family history is a strong predictor of stroke, even after
adjustment for traditional risk factors, suggesting the
existence of a substantial genetic component [2]. How-
ever, the genetic architecture of this common complex dis-
ease remains elusive. Given the extreme complexity of
genetic and environmental contributions to stroke, evalu-
ation of the precursor (risk) phenotypes, especially the
quantitative ones, may reduce heterogeneity and increase
statistical power for susceptibility gene discovery. Our
Family Study of Stroke Risk and Carotid Atherosclerosis is
uniquely designed to evaluate genetic contribution to cer-
ebrovascular risk phenotypes, such as carotid intima-
media thickness and left ventricular mass (LVM).
LVM is an important risk factor for stroke. In the Framing-
ham Heart Study, the highest quartile of LVM was associ-
ated with a 2.7-fold increased risk of stroke when
compared to the lowest quartile of LVM, after adjusting
for age, sex, systolic blood pressure, treatment of hyper-
tension and other established stroke risk factors [3]. We
have also demonstrated that LVM is significantly associ-
ated with an increased risk of stroke and combined vascu-
lar events in a multi-ethnic cohort comprised
predominately of Hispanics [4]. The adjusted hazard ratio
for the combined endpoint of myocardial infarction,
stroke, or vascular death was 1.34 per one standard devia-
tion (SD) increase in LVM [95% CI 1.10 to 1.63].
As a quantitative trait, LVM is highly heritable. In the
Framingham family study the heritability of LVM was esti-
mated to be 0.24–0.32. [5] In the HyperGEN offspring
study, the estimates of LVM heritability were 0.46 in Afri-
can-Americans and 0.47 in Caucasians [6]. Heritability of
LVM among Japanese subjects living in Hawaii was esti-
mated to be 0.6 [7], similar to what we have seen in our
sample of Caribbean Hispanics [8]. Consistent with a
strong genetic influence, heritability estimates for LVM are
often higher in twin studies than in sibling or family
cohorts; the estimate is as high as 70% for monozygotic
twins [9,10]. These studies suggested a substantial genetic
contribution to LVM variations and encouraged an effort
to map the quantitative trait loci (QTL) for this trait.
Previously, we have published a comprehensive heritabil-
ity analysis on LVM as well as adjusted LVM measure-
ments: LVM divided by body surface area or height;
relative wall thickness; LV end-diastolic diameter; LV end-
systolic diameter; interventricular septum thickness; and
posterior wall thickness. The estimates of heritability for
these LV measurments ranged from 0.23 to 0.65 after dif-
ferent adjustment for covariates, with LVM demonstrating
the highest heritability (0.47 to 0.65 in different models)
[8]. Therefore, we focused our QTL mapping effort on
LVM in this study. In addition, we implemented the
Ordered-subset Analysis (OSA) based on LVM-related
covariates to strengthen linkage, narrow the critical link-
age region and identify a more etiologically homogeneous




The details of the family study design have been described
elsewhere. [11] In brief, probands for the family study
were selected from the population-based North Manhat-
tan Study (NOMAS). In order to maximize the genetic
component in the families for stroke risk phenotypes and
thereby enhance our chance to map susceptibility genes,
we assembled a high-risk Caribbean Hispanic family data-
set using the following criteria to define a qualifying
proband: (1) reporting a sibling with a history of myocar-
dial infarction or stroke; or (2) having 2 of 3 quantitative
risk phenotypes (maximal carotid plaque thickness, left
ventricular mass, or homocysteine level above the 75th
percentile in the NOMAS cohort). The majority of the
probands (80%) were recruited based on the first criteria.
Families of the eligible probands were considered for
enrollment if the proband was able to provide a family
history, obtain the family member's permission for the
research staff to contact them, and had at least two addi-
tional first-degree relatives able to participate. After the
proband was contacted, the study coordinator followed
up with the relatives to explain the study and solicit par-
ticipation. Although the proband was identified in North-
ern Manhattan, we enrolled family members in New York
at Columbia University and in the Dominican Republic at
the Clinicas Corazones Unidos in Santo Domingo. All
subjects provided informed consent to participate in the
study and the study was approved by the Institutional
Review Boards of Columbia University, University of
Miami, and the National Bioethics Committee and the
Independent Ethics Committee of Instituto Oncologico
Regional del Cibao in the Dominican Republic (DR).
Demographic, socioeconomic and risk factor data were
collected through direct interview of each family member
based on instruments developed in NOMAS [12]. Exten-
sive questionnaires regarding hypertension, diabetes,
smoking, alcohol use, and physical activity were com-
pleted using systematic instruments. Measurements of
anthropometrical indices including height, weight, hip
and waist measures and skin-fold thickness were
obtained, as were serial blood pressures. Fasting blood
was collected and processed for lipids (total cholesterol,
LDL, triglyceride, HDL), glucose, electrolytes, and creati-
nine. Storage of buffy coats and extraction of DNA was
done by the Columbia University Genome Center.Page 2 of 8
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Baseline transthoracic echocardiography was done on
1360 Dominican family members and probands in the
Family Study of Stroke Risk and Carotid Atherosclerosis.
Standard two-dimensional echocardiography, including
color-Doppler flow study was performed according to the
guidelines of the American Society of Echocardiography
[13]. Special attention was paid to obtaining high quality
parasternal long axis views of the left ventricle, from
which left ventricular end-diastolic diameter (LVDD), left
ventricular end-systolic diameter (LVSD), interventricular
septum (IVS), and posterior wall thickness (PWT) were
derived [14]. Sonographer performance was monitored
quarterly after review of a random sample for technical
adequacy of the images. Readers were blinded to familial
relationships and vascular risk factors. Inter-observer var-
iability for the variables of interest ranged between 8%
and 10%. LVM was calculated according to the modified
American Society of Echocardiography (ASE) formula:
LVM = 0.8 [1.04 (LVDD + IVS+PWT)3 - (LVDD)3] +0.6.
[15].
Genotyping and Quality Control
DNA was sent to the Center for Inherited Disease Research
(CIDR) for genotyping. A set of 405 microsatellite mark-
ers were genotyped at an average interval of 10 centimor-
gan (cM) across the genome. Autosomal microsatellite
genotypes were used to verify and adjust family structure
using the program PREST. [16] In order to do so, the Max-
imized Log-Likelihood Ratio (MLLR) test statistics were
computed to compare the putative relationship between
pairs of individuals to those constructed based on the
autosomal genotypes. Relationships with a p-value for the
MLLR test of < 0.000001 in a consistent manner across the
family were considered in error. Estimated kinship coeffi-
cients and identity by descent (IBD) estimates were used
to rearrange family structure as needed. Finally, family
structure was confirmed by running PREST again. Mende-
lian error checking was performed on the final family
structure using Pedcheck [17].
Statistics
Heritability was evaluated using a pedigree-based maxi-
mum-likelihood method implemented in SOLAR. [18]
Variance components methodology as implemented in
SOLAR has emerged as a powerful method to detect link-
age of quantitative traits and was used to calculate two-
point and multipoint LOD scores [19,20]. Ascertainment
correction was automatically incorporated in the linkage
analysis. First, marker-specific IBD were computed using
the David and Weeks Monte Carlo algorithm for each
marker. After marker-specific IBDs were merged together
into one single file, multipoint IBDs were calculated using
a 1 cM grid. Empirical p-values for LOD scores were calcu-
lated based on 10,000 replicates in which a fully-inform-
ative marker, unlinked to LVM, was simulated and used to
compute possible LOD scores. Since SOLAR requires that
quantitative traits be normally distributed and properly
scaled, LVM measurements were natural-log transformed
and multiplied by 10. To ensure normality, two outliers,
whose LVM measurements were beyond three standard
deviations from the mean, were dropped from further
analysis.
To decide the covariates that should be included in esti-
mating heritability and calculating LOD scores, a poly-
genic covariate screening implemented in SOLAR was run
to screen age, sex, smoking, diabetes, dyslipidemia, hyper-
tension, and body mass index (BMI). Interaction between
age and sex was automatically included in SOLAR. A per-
missive threshold of p < 0.1 was used for this evaluation
to allow for inclusion of any potentially significant covari-
ates. Hypertension was defined as reported history of high
blood pressure, systolic blood pressure ≥ 140 mmHg,
diastolic blood pressure ≥ 90 mmHg, or use of antihyper-
tensive medication. Smoking was defined as never versus
ever. Dyslipidemia was defined as a history of hyperlidi-
demia or total cholesterol greater than 240 mg/dL.
For the OSA, trait-related quantitative covariates were
used to rank families for a more homogeneous subset
[21]. LOD scores calculated in the overall linkage analysis
for each family were used as input. Families were sequen-
tially introduced into linkage analysis by the order of
increasing or decreasing covariate values until the maxi-
mum evidence for linkage was achieved. A permutation
procedure was implemented to generate an empirical p-
value for the significance of the increase in the LOD score
from the overall dataset to OSA identified subset. Specifi-
cally, 10,000 random family orderings were permuted
and the maximum LOD scores from each of the random
orderings were compared with the OSA results to derive
the empirical p-value. All statistical analyses were per-
formed using SAS v9.1.3 (SAS Institute Inc., Cary, NC)
unless specified otherwise.
Results
Overall, 110 families with high vascular disease burden
(Dominican Republic 100, Puerto Rico 4, Cuba 2, Ecua-
dor 2, Nicaragua 1, and Colombia 1) were enrolled in our
family study. Seventy percent of the subjects were enrolled
in Northern Manhattan and 30% in the Dominican
Republic. In order to reduce population stratification, we
restricted our QTL mapping to the 100 Dominican fami-
lies, which was composed of 2182 individuals. The mean
family size was 22 ± 11 with median of 20, and range of
4–87. LVM measurements and DNA samples were availa-
ble for 1360 subjects from the 100 Dominican families.
Among the 1360 individuals, there were 1207 sib pairs,
362 half-sib pairs, and 1713 avuncular pairs. With ourPage 3 of 8
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with heritability estimates greater than 0.18 at a LOD
score threshold of 2.0. The mean age of the study cohort
was 46 years. The mean LVM was 174.85 ± 56.14 (Table
1). Men had significantly greater mean LVM than women
(201.42 vs 158.15, p < 0.0001).
The polygenic covariate screening identified age-sex inter-
action, sex, ever smoking, systolic blood pressure (SBP),
and BMI as significant covariates. Heritability and LOD
scores were calculated adjusting for these covariates. The
significant covariates together explained 0.33 of the total
LVM variance. The heritability estimate of LVM is 0.58 (p
< 0.0001) for the remaining variance of LVM after adjust-
ing for the significant covariates.
To localize the genetic loci affecting LVM variations, we
completed a QTL mapping on LVM. This analysis revealed
a significant region on chromosome 12p11 with peak
marker at D12S1042 (MLOD = 3.11, empirical p value =
0.0003) (Figure 1). The one-LOD unit down critical inter-
val extends from approximately 25 Megabase (Mb) to 51
Mb on chromosome 12, encompassing 181 annotated
genes. No evidence for linkage (LOD > 1.5) was found in
any other region through the genome (data not shown).
Estimation of the locus specific heritability is 0.25 at
D12S1042 and this locus accounted for 43% of the total
heritability of LVM in our dataset.
To better characterize the prominent linkage region on
12p11, we performed OSA to further reduce phenotypic
heterogeneity. In this analysis, trait-related quantitative
covariates were used to rank families for a more homoge-
neous subset. We chose SBP, BMI, and waist circumfer-
ence (WC) as the covariates to order families because high
blood pressure and obesity, especially elevated waist cir-
cumference (WC), are major risk factors that lead to an
increase of LVM in general population [22-24]. We
ordered families by family average SBP, BMI, and WC.
OSA results based on high to low (H-L) or low to high (L-
H) ranking of the three covariates are listed in Table 2. The
OSA maximum LOD score was increased in all H-L rank-
ings (LOD = 3.81 to 4.45) but was not changed in the L-
H rankings (LOD = 3.14 to 3.40), when compared to the
overall analysis. Permutation tests were performed to
evaluate the significance of increases in LOD scores.
Among all the OSA ranking strategies that led to a higher
LOD score, ordering families by decreasing average WC
significantly increased the evidence for linkage (LOD =
4.45) (p = 0.0045 for increase in LOD score). In addition
to significantly strengthening the linkage, this ranking
strategy also greatly reduces the one-LOD unit down sup-
porting interval size from 26 Mb to 14 Mb (Figure 1). The
narrowed critical linkage region extends from 25 Mb to 39
Mb on chromosome 12 harboring 55 annotated genes.
The OSA defined subset included 54 families with high
WC. The average WC was 38.4 inches for the OSA subset
Table 1: Sociodemographic, vascular risk factors, and left ventricular mass measurements
Males Females Total
(N = 525) (N = 835) (N = 1360)
n % n % n %
Hypertension 200 38.10 340 40.72 540 39.71
Diabetes 77 14.67 109 13.05 186 13.68
Coronary artery disease* 80 15.24 164 19.64 244 17.94
Ever smoking 217 41.33 256 30.66 473 34.78
≥ High School Education 266 50.67 399 47.78 665 48.9
Enrolled in the DR 164 31.24 262 31.38 426 31.32
Mean ± SD Mean ± SD Mean ± SD
Age 44.59 ± 17.21 47.10 ± 17.24 46.13 ± 17.26
Body mass index (kg/m2) 28.44 ± 5.34 28.98 ± 6.06 28.77 ± 5.80
Waist circumference (inch) 37.99 ± 5.18 35.57 ± 5.60 36.50 ± 5.57
Triceps skinfold thickness (mm) 21.12 ± 10.89 30.68 ± 10.62 27.00 ± 11.69
Fast glucose (mg/dl) 94.92 ± 44.12 89.38 ± 31.62 91.52 ± 37.04
Total cholesterol (mg/dl) 183.31 ± 44.25 186.97 ± 40.58 185.56 ± 42.05
LDL (mg/dl) 110.76 ± 35.64 110.52 ± 34.96 110.61 ± 35.21
HDL (mg/dl) 44.80 ± 11.77 53.34 ± 13.55 50.05 ± 13.55
Triglyceride (mg/dl) 141.95 ± 116.77 115.46 ± 67.09 125.66 ± 90.43
Systolic blood pressure (mmHg) 124.18 ± 18.05 120.35 ± 20.69 121.82 ± 19.80
Diastolic blood pressure (mmHg) 79.05 ± 10.84 75.78 ± 10.38 77.04 ± 10.68
Left ventricular mass 201.42 ± 60.88 158.15 ± 45.65 174.85 ± 56.14
*Coronary artery disease was defined as having a history of bypass surgery, angioplasty, or myocardial infarction.Page 4 of 8
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(Table 2).
Discussion
Using well-characterized, extended Dominican Republic
families, we mapped a novel QTL for LVM on chromo-
some 12p11. This QTL influences LVM independent of
other risk factors such as gender, age, hypertension, BMI,
and smoking. By implementing OSA to reduce phenotype
heterogeneity, we have greatly strengthened the evidence
for linkage, narrowed the linkage region and identified a
sub-phenotype that has concentrated genetic effects from
chromosome 12p11. Our findings provide a well-defined
chromosome region and phenotype for future validation
and fine mapping studies to localize genes controlling
LVM.
The majority of genetic studies on LVM phenotype to date
have focused on candidate genes derived from biological
pathways that have impact on the LVM phenotype, such
as genes implicated in myocardial cell growth/remode-
ling, calcium homeostasis, extracellular matrix, hemody-
namic load, and blood pressure regulation.
Polymorphisms in several genes have been associated
with LVM, such as the 825C/T polymorphism in the G
protein beta subunit (GNB3) gene, [25-27] polymor-
phism in the beta-1 adrenergic receptor (beta-1 AR) gene,
[28], the -344C/T polymorphism and a gene conversion
in intron 2 in the aldosterone synthase gene, [29,30] and
the polymorphism in the angiotensin-converting-enzyme
(ACE) gene. [31] However, the association results have
been conflicting [10,32]. Recently, a meta-analysis of 485
reports concluded that the -344C/T polymorphism in the
aldosterone synthase gene is not significantly associated
with LVM [33].
Other approaches to identify the underpinning genes for
a disease-associated trait are unbiased genomic
approaches, such as genome-wide linkage and association
studies. These studies do not require a priori knowledge on
the molecular basis of phenotypic variations and have
advantages in identifying unknown/unexpected genes
and pathways for complex traits. Previously, two genome-
wide studies of LVM as a quantitative trait have been
reported. Both of them were conducted in Caucasian pop-
ulations [34,35]. One was completed in white British fam-
ilies with hypertension and another one was conducted in
families from the Framingham Heart Study. In the British
study, suggestive evidence for linkage was found on chro-
mosome 5p (MLOD = 1.6) for echocardiography-derived
LVM (echo-LVM), and on chromosome 7q (MLOD = 1.7)
and 12q (MLOD = 2.2) for electrocardiography-derived
LVM (ECG-LVM) [34]. In the Framingham Heart Study,
100,000 of single nucleotide polymorphisms (SNPs) were
tested for association with LVM. None met the genome-
wide significance level. Three SNPs with a nominal p-
Multipoint linkage plots for left ventricular mass on chromo-some 12 in overall families and subset families defi ed by ordered-subset nalysi on waist circumferenceFigu  1
Multipoint linkage plots for left ventricular mass on 
chromosome 12 in overall families and subset fami-
lies defined by ordered-subset analysis on waist cir-
cumference. Maximum multipoint LOD scores were 
plotted along the chromosomal position in centimorgans 
(cM) on chromosome 12. Horizontal lines indicate the one-
LOD unit down supporting intervals. All 100 families were 
used in the overall analysis and the LOD score is depicted by 
solid line. In the ordered-subset analysis, the families were 
ranked by mean waist circumference from high to low and 
sequentially introduced to linkage analysis until the maximum 
LOD score was achieved. 54 families with the highest waist 
circumference were used in the final analysis and the LOD 
score is depicted by the dashed line.
Table 2: Ordered-Subset analysis results on chromosome 12 p11.
Covariate Position (cM) Maximum OSA 
Lod
Empircal P value* Number of 
Subset Families
Mean Covariate 
Value (SD) in 
subset
Mean Covariate 
Value (SD) in 
other families
WC (H to L)† 49 4.45 0.0045 54 38.4 (1.5) 34.4 (1.5)
WC (L to H)† 49 3.14 1 100 36.5 (2.5) NA
SBP (H to L) 49 3.81 0.1075 84 124.2 (6.9) 112.6 (3.0)
SBP (L to H) 49 3.40 0.4228 94 121.1 (6.1) 141.5 (4.5)
BMI (H to L) 49 3.89 0.0759 78 30.0 (2.2) 25.3 (1.2)
BMI (L to H) 49 3.16 0.7716 98 28.8 (2.7) 35.5 (1.2)
† H to L: high to low; L to H: low to high; * p value is based on 10,000 permutations.Page 5 of 8
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11. One SNP is located within a heat shock protein gene
HSPA8; the other two SNPs are not located in or near
known genes. Linkage analysis revealed strong evidence
for linkage on chromosome 5q (MLOD = 4.4) and sugges-
tive evidence for linkage on chromosomes 1q and 8q
(MLOD = 2.4).
There is no overlap among the QTLs delimited in the Brit-
ish, the Framingham Heart, and the current studies. One
possible explanation is that the unique ethnic population
in our study may have a different genetic basis for LVM
than Caucasians analyzed in the other two studies. How-
ever, the lack of replication even between the British and
Framingham studies as well as the conflicting candidate
gene studies, underscore the challenges in genetic analysis
of complex traits: the genetic basis is likely to be complex
and heterogeneous, involving multiple genes each with
moderate effect and interaction with environmental fac-
tors. Within a given dataset, only one or two loci with the
strongest effect in that population can be detected. In our
study, the 12p11 QTL only accounts for less half of the
total heritability of LVM. Other loci that have smaller
effect sizes are still at large due to the limited power of the
current dataset. Future studies in a similar population,
including meta analyses are needed to catalogue all the
genetic causes for the inter-individual LVM variations.
To reduce heterogeneity, stratification analysis based on a
trait-related variable has been proposed in genetic studies
of complex traits. The OSA ranks families by a trait-related
variable and sequentially introduces the families to the
linkage analysis until the maximum evidence of linkage is
observed [36]. The subset defined by OSA is likely to rep-
resent a more etiologically homogeneous sample and thus
increases the statistical power. Furthermore, the more
homogeneous phenotype defined in the OSA subset pro-
vides insight to guide further analysis to pinpoint the
genetic variants contributing to the trait. For example, in
the GENECARD family study of coronary artery disease
(CAD), OSA has identified a subset of families with very
early age-of-onset (mean age-of-onset = 37.8 years) with
strong evidence for linkage on chromosome 7p (LOD =
4.2). This finding was used to guide further association
studies in subjects with early onset CAD and led to the dis-
covery of the Neuropeptide Y gene polymorphism as
genetic risk factor for atherosclerosis [37].
Using OSA, we found that the linkage signal on chromo-
some 12p11 is mainly from families with high WC. To
exclude the possibility that we mapped a locus for WC
instead of LVM, we performed a linkage analysis on WC
and found no evidence suggesting that the signal on
12p11 is driven by WC (LOD = 0 at D12S1042 for WC).
Therefore, the 12p11 linkage is a bona fide QTL for LVM
and genes under this QTL interact with visceral obesity to
influence inter-individual LVM variations. Adipose tissue
is an active organ that secretes a variety of bioactive pep-
tides. Several proteins of the renin angiotensin system, an
essential regulatory axis for blood pressure, are expressed
in adipose tissue. [38] Among them, angiotensinogen
(AGT), angiotensin receptors type I (AT1), and ACE have
higher expression in visceral than subcutaneous adipose
tissue. Indeed, plasma AGT and plasma ACE activity are
higher in obese individuals. [38] One possible scenario is
that the candidate gene(s) in 12p11 QTL interact(s) with
the bioactive peptides produced in visceral adipose tissue,
such as ACE, to affect LVM. This interaction could con-
found phenotype-genotype correlations and should be
taken into account in future fine-mapping studies.
The OSA based on BMI did not significantly enhance the
linkage evidence despite that BMI and WC are correlated
measurements, suggesting that WC provided additional
information to BMI in the analysis of LVM. Consistently,
recent reports from Rodrigues et al. [39] and Tsioufis CP
et al. [40] showed that WC is an important predicator of
LV hypertrophy and LV diastolic dysfunction. Further-
more, the impact of WC on LV structure and function
seemed to be especially strong in women in those two
studies. This gender specific effect should be considered in
future studies in population-based cohort. The OSA based
on SBP did not identify any subset that was significantly
different from the randomly ordered families. However,
our study is limited by the single clinic measurement of
blood pressure and antihypertensive treatment. Blood
pressure variation throughout the day is better predictor
of left ventricular hypertrophy than a single clinic meas-
urement, and antihypertensive treatment may reduce left
ventricular hypertrophy depending on how long the
patient has been treated. These could obscure the correla-
tion between blood pressure and LVM.
It is worth noting that in the HyperGEN study suggestive
evidence for linkage (LOD = 1.99) for LV geometry was
found at the same peak marker (D12S1042) for LV mass
in our study [41]. LV geometry is a combination of LV
mass and relative wall thickness (RWT) of LV, with LV
mass contributing to forming the different LV geometric
patterns and RWT being an index of concentric geometry.
Although the LV measurement is not exactly the same
examined in our study, the encouraging LOD score at the
same chromosomal location as found in the HyperGEN
study corroborates our findings of chromosome 12p11 as
a potential locus for LVM due to similarity between LV
mass and LV geometry. Nonetheless, further validation
studies on LVM are desired to confirm the QTL.
Our success in mapping a strong QTL relies on the
strength of our study design. We focused on one ethnic
group and used a family study design to minimize the
effects of population substructure. All the families havePage 6 of 8
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measurements of the quantitative phenotype. The
extended family structure (average family size of 20) in
our dataset provides unprecedented information content
and statistical power. The QTL mapping approach also
offers additional statistical advantages over discrete traits.
A major limitation of our study is that we did not pinpoint
the causal genetic variations that lead to increased LVM.
This study is only the first stage to elucidate the genetic
basis for LVM. Looking through all the genes under the
12p11 linkage peak did not find any gene that would have
an obvious effect on LVM based on the current knowl-
edge. However, the molecular basis of increased LVM is
not clear and many genes' functions are not fully under-
stood. We plan to perform fine mapping study across the
linkage peak to narrow the critical region and identify the
candidate gene in future studies.
Most genetic studies of cardiovascular disease have
focused on non-Hispanic populations [42-46] with a few
exceptions such as the San Antonio Family Heart Study
and the Multi-ethnic Study of Atherosclerosis (MESA)
[47,48]. Our family study provides essential data to fill the
gaps in our knowledge of the genetics of cerebrovascular
risk phenotypes in minority populations.
Conclusion
With the unbiased genome-wide approach, we mapped a
novel QTL for LVM, a significant risk phenotype for stroke
and vascular events. The strong evidence for linkage on
chromosome 12p11 warrants further validation and fine
mapping efforts. In addition, our family study provides
unique data on the genetics of cerebrovascular risk pheno-
types in an understudied minority population.
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